CS-8958 Clinical Pharmacology study -Evaluation of intrapulmonary pharmacokinetics of CS-8958 and laninamivir after a single inhaled dose of CS-8958 in healthy Japanese subjects
Latest Information Update: 24 Sep 2018
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
- 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
- 03 Jun 2016 New trial record